About
Experienced physician with a demonstrated history of working in the hospital & health…
Activity
-
Drs. @pankitvachhani and @bose_prithviraj will present our two encore posters today at the 2024 Society of Hematologic Oncology Annual Meeting (SOHO…
Drs. @pankitvachhani and @bose_prithviraj will present our two encore posters today at the 2024 Society of Hematologic Oncology Annual Meeting (SOHO…
Liked by Lucia Masarova
-
“In both of those areas, you always want to innovate and create something that did not exist before," says our Dr. Hagop Kantarjian of the…
“In both of those areas, you always want to innovate and create something that did not exist before," says our Dr. Hagop Kantarjian of the…
Liked by Lucia Masarova
-
September marks the start of Blood Cancer Awareness Month! 🎗️ Did you know that Myeloproliferative Neoplasms (MPNs) are rare yet challenging…
September marks the start of Blood Cancer Awareness Month! 🎗️ Did you know that Myeloproliferative Neoplasms (MPNs) are rare yet challenging…
Liked by Lucia Masarova
Experience
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
Activities and Societies: Medical Student Society
Licenses & Certifications
-
-
-
GCP - Clinical Research and Trials in Oncology
ECCRT - European Centre for Clinical Research Training
Issued
Publications
-
Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia
Br J Haematology
-
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era
Cancer
-
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
Cancer
-
Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported
Leuk Research
-
Novel treatment strategies for myeloproliferative neoplasms
Rinsho Ketsueki 60(9):1176-1185
-
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
Leukemia. PMID: 31628430
-
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
Curr Hematol Malig Rep 14(4):310-327
-
Emerging drugs for essential thrombocythemia.
Expert Opin Emerg Drugs:1-13
-
The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Clin Adv Hematol Oncol 17(5):299-307
-
The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
Ann Hematol 97(11):2071-2080
-
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
Blood
-
Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere
J Clin Oncol
-
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice
Adv Exp Med Biol. 995, 97-116
-
Treatment of The Myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 Inhibitor
Ann Oncol 29(8):1880-1882
-
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Eur J Haematol 100(3):257-263
-
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Ann Hematol 97(1):109-121
-
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Blood
-
Immunotherapy based approaches in myelofibrosis
Expert Review in Hematology
-
Therapy related myelofibrosis does not appear to exist
Blodd Advances
-
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
Leuk Research
-
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
Lancet Haematol.
-
Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy
ASH 2016
Abstract 4687.
Other authors -
-
Clinical associations of cytogenetic abnormalities in patients with primary and post-essential thrombocythemia / post-polycythemia vera myelofibrosis
ASH 2016
Abstract 4265.
Other authors -
-
Cytogenetic risk stratification in primary versus post-essential thrombocythemia and post-polycythemia vera myelofibrosis
ASH 2016
Abstract 4250.
Other authors -
-
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
ASH 2016
Abstract 4266.
Other authors -
-
Clinical characteristics of patients with primary or post-polycythemia vera/post-essential thrombocytopenia myelofibrosis and deletion 13q.
SOHO 2016
Abstract 114.
Other authors -
-
Does occurrence of other malignancy after essential thrombocythemia (ET) and polycythemia vera (PV) influence their rate of transformation to myelofibrosis (MF)?
SOHO 2016
Abstract 116.
Other authors -
-
Therapy-Related Myelofibrosis does not appear to exist
SOHO 2016
Abstract 115.
Other authors -
-
Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis
Blood
Other authors -
-
Co-occurrence of lymphoproliferative neoplasm and myelofibrosis
Pan-Pacific Lymphoma Conference
Abstract 61.
Other authors -
-
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis
Leuk Lymphoma 2016
Other authors -
-
Harnessing the Immune System against Leukemia: Monoclonal antibodies and Checkpoint Strategies for AML.
Springer
Adv Exp Med Biol. Book Chapter N. II.
Other authors -
-
Immune Checkpoint Approaches in AML: A Next Frontier?
Targeted Therapies Journal
Pending publishing.
Other authors -
-
Do patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis?
ASH 2015
Abstract 4069.
Other authors -
-
Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results after a median 7-year follow-up of a Phase 2 study
ASH 2015
Oral presentation, abstract 60.
Other authors -
-
Clinical relevance of other malignancies in patients with myelofibrosis.
The 8th International Congress on Myeloproliferative Neoplasms, Myelodysplasia and Chronic Myeloid Leukemia
Abstract 102
Other authors -
-
Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics
Leuk Lymhpoma
Other authors -
-
Biological therapy in clinical oncology. Selected Chapters in Medical Oncology. Chapter V.
Rowex, Bratislava. ISBN 978-80-969863-6-1.
Other authors -
-
Micafungin as empirical antifungal therapy in haematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.
Leuk Lymphoma.
54(5):1042-7. Epub 2012 Nov 15.
Other authors -
-
Invasive aspergillosis in patients with haematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005- 2009
Int J Infect Dis
7(2): 101-109
Other authors -
-
Biological treatment in oncology
Via practica
8 (6): 265- 269.
Other authors -
-
Treatment of invasive fungal diseases. 3th Fungal Forum
Onkologia
5(5): 304-305
-
Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance
Leuk Research
-
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome
Leuk Res. 2015
S0145-2126(15)00132-0.
Other authors -
-
Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: a single-center experience in 1100 myelofibrosis patients
J Clin Oncol 34, 2016
Abstr 7068
Other authors -
-
Does Therapy- Related Myelofibrosis Exist? Analysis of 1100 Myelofibrosis Cases from a Single Institution
J Clin Oncol 34, 2016
Abstr e18558
Other authors -
-
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience
Leuk Lymphoma. 2015 Jun 19:1-3
Other authors -
Projects
-
Allo - Transplant in Patients with Myelofibrosis vs Conservative Therapy, MDACC
- Present
-
Comparison of Transplant vs non Transplant Therapies for Myelofibrosis, CBMTR study
- Present
Active contribution with >800 patients with MF and non-Transplant from MDACC
Principal Data Analyst -
MDACC database 1964-2015 Myelofibrosis patients
- Present
-
Observation / survey of patients with invasive aspergillosis.
-
Healthcare resource utilization in hospitalized febrile neutropenia (FN) patients treated with chemotherapy for solid tumors and haematological malignancies in Bulgaria,Czech Republic and Slovakia as observed in clinical practice
-
.
-
Invasive aspergillosis in patients with haematological malignancies in the Czech and Slovak Republics:Fungal InfectioN Database (FIND) analysis. The Czech Leukemia Study Group for Life (CELL).
-
-
Invasive candidiasis in selected heamatology departments in the Czech Republic and Slovakia. The Czech Leukemia Study Group for Life (CELL).
-
Honors & Awards
-
Best Clinical Fellow 2016/2017
MD Anderson Cancer Center, Department of Leukemia
-
ASH Merit Achievement Award
American Society of Hematology
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
-
The Shannon Timmins Fellowship for Leukemia Research Award
MD Anderson Cancer Center
-
ASH Merit Achievement Award
American Society of Hematology
Oral presentation: Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results after a median 7-year follow-up of a Phase 2 study.
-
Best Poster Award
Slovak Lymphoma Society
Second Autotransplant in Patients with Hodgkin‘s Lymphoma – NCI Experience
-
Academic Award of the Dean of the Faculty of Medicine
Univerzita Komenskeho V Bratislave
Graduation Magna Cum Laude
Languages
-
English
-
-
Slovak
-
-
Czech
-
-
German
-
-
Russian
-
Organizations
-
ECFMG
Member
- Present -
Slovac Oncology Society
Member
- Present -
Slovac Medical Society
-
- Present -
American Society of Clinical Oncology
-
-
American Society of Hematology
-
-
European Society of Medical Oncology
-
-
Society of Hematologic Oncology
-
More activity by Lucia
-
👉👉👉Proud to have Co-Chaired the inaugural #MPNWorkshopNC24 with my great friend & amazing colleague Dr Ruben Mesa, MD !!! What an amazing meeting…
👉👉👉Proud to have Co-Chaired the inaugural #MPNWorkshopNC24 with my great friend & amazing colleague Dr Ruben Mesa, MD !!! What an amazing meeting…
Liked by Lucia Masarova
-
👇 Very much looking forward to this research Town Hall with this group of #MPNexperts. An absolute honor to participate 🫠 #MPNsm MD Anderson Cancer…
👇 Very much looking forward to this research Town Hall with this group of #MPNexperts. An absolute honor to participate 🫠 #MPNsm MD Anderson Cancer…
Shared by Lucia Masarova
-
👉👉👉Honored to be a featured MPN faculty speaker for this upcoming MD Anderson Cancer Center Research Town Hall with focus on Myelofibrosis: The…
👉👉👉Honored to be a featured MPN faculty speaker for this upcoming MD Anderson Cancer Center Research Town Hall with focus on Myelofibrosis: The…
Liked by Lucia Masarova
-
A few weeks ago we hosted the 2nd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms in Boston, USA 🇺🇸 🩸 📣 Take…
A few weeks ago we hosted the 2nd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms in Boston, USA 🇺🇸 🩸 📣 Take…
Liked by Lucia Masarova
-
A study by Tapan Kadia, meixian huang, Naveen Pemmaraju, MD, et al., of MD Anderson Cancer Center, found that CK0801 is safe and effective in…
A study by Tapan Kadia, meixian huang, Naveen Pemmaraju, MD, et al., of MD Anderson Cancer Center, found that CK0801 is safe and effective in…
Liked by Lucia Masarova
Other similar profiles
Explore more posts
-
OncoDaily
Immunogenic cell death-based cancer vaccines promising prospect in cancer - Maryam Diba Tehran University of Medical Sciences https://lnkd.in/ge2rjrnB #oncodaily #oncology #cancer #cancervaccines #immunotherapy #immunogeniccelldeath #ICD #DAMPs #neoantigens #personalizedmedicine #chemotherapy #radiotherapy #photodynamictherapy #oncolyticviruses #antitumorimmunity #immunogenicity #antigenpresentation #resistance #apoptosis #necroptosis #ferroptosis #pyroptosis
4 Comments -
Journal of Research in Medical Sciences (JRMS)
🩺🌸 Assessing Demoralization in Breast Cancer Patients: Persian Version of the Demoralization Scale (DS-II) 🌸🩺 📚 Just Published in the Journal of Research in Medical Sciences (March 2024) 📚 Background: Demoralization, characterized by existential distress and despair, is common among cancer patients. The Demoralization Scale (DS-II), a self-administered tool with 16 items, assesses two factors: meaning and purpose, and distress and coping ability. Key Findings: Study Cohort: 240 women with breast cancer participated. Reliability: DS-II demonstrated good internal consistency (Cronbach’s alpha: 0.67 for meaning and purpose, 0.72 for distress and coping ability, and 0.81 for the total score). Validity: Confirmatory factor analysis confirmed the two-factor structure. Convergent and divergent validity were also established, showing correlations with related constructs. Conclusion: The Persian version of DS-II exhibits robust psychometric properties. It serves as a reliable tool for assessing demoralization in women with breast cancer, aiding in comprehensive patient care. 🔗 Read more: https://lnkd.in/duj5-359 This study contributes to understanding and addressing the psychological aspects of breast cancer, facilitating tailored interventions and support for affected individuals. #BreastCancer #Demoralization #PsychometricAssessment #MedicalResearch #JRMS 🎗️🧠
-
Video Journal of Oncology (VJOncology)
NEW from #ESMOGI2024 🎥 🇩🇪 Salwan Al Mutar MD MS, MD, UT Southwestern Medical Center spoke to us on: 🌟 Evaluating the future role of #VEGFinhibitors in #pancreaticcancer - #Nintedanib, an oral kinase inhibitor targeting #VEGFR, #PDGFR, and #FGFR, was shown to have encouraging efficacy, and was well tolerated in a Phase Ib study (NCT02902484). It additionally had low rates of VEGF inhibitor-related adverse events such as #hypertension 🌟 Advances in #molecular targeted therapies for #pancreaticcancer - overview of current research on targeted therapies for #pancreaticcancer. Trials are underway assessing #KRASinhibitors, including pan-KRAS and #KRASG12C inhibitors, as well as agents targeting claudin 18.2 and MTAP loss 🌟 Phase I trial of #nintedanib and #chemotherapy in metastatic PDAC - Phase Ib study (NCT02902484) of #nintedanib, an #oralkinaseinhibitor targeting #VEGFR, #PDGFR, and #FGFR, with #gemcitabine and #nab-paclitaxel in #metastatic #pancreaticductaladenocarcinoma (PDAC). Results showed that #nintedanib 200 mg twice daily was safe and tolerable and the most common adverse events included anemia, neuropathy, and fatigue Learn more 👉 https://lnkd.in/eJ35h6nx #VJOncology #Oncologynews
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Lucia Masarova
-
Lucia Masarova
Freelance language instructor ve společnosti Lucia Masárová
-
Lucia Masarova
Sr. Data Analyst at HG Insights
-
Lucia Masarova
Financial Manager at European Research Executive Agency (REA)
-
Lucia M.
Marketing and Entrepreneurship specialist
12 others named Lucia Masarova are on LinkedIn
See others named Lucia Masarova